If The MiniMed Split-Off Stalls, What Happens To Your Medtronic Stock?
Medtronic (MDT) is offering its shareholders a swap: hand in Medtronic shares and receive shares of MiniMed, its diabetes business. The offer is worth about $4 billion, and a Barron’s report on October 2 said it is losing its allure. If you own Medtronic, you may wonder what a stalled swap would leave you holding. First, where does the swap stand today?
What Is Known About Medtronic’s MiniMed Swap
On the September 1 call for fiscal Q1 2027, analysts asked why the split-off had not yet been announced. Management answered that there was no hesitation and no change in schedule. It said it would separate MiniMed when the economics were best for shareholders, and that it intends to close before the fiscal year ends.
The offer is now formally on the table. On September 14, 2026, MiniMed filed a registration statement for Medtronic’s offer to exchange MiniMed shares for Medtronic shares. Medtronic is offering up to 80.1% of MiniMed’s outstanding stock.
The October 2 report came after that filing, and it bears on the timing: an offer that holders find less attractive may be harder to finish on schedule.
How Would A Stalled Swap Affect Medtronic Holders?
The swap covers about $4 billion of stock, at a company with a market value of $112.5 billion.
You would see a stall first in the share count. In a completed swap, holders hand Medtronic shares back to the company in exchange for MiniMed shares. The offer is more than three times the $1.2 billion Medtronic spent on buybacks over the past twelve months. Management also said on the September 1 call that it has no specific buyback plans, though it left the door open if conditions are right. Without the swap, Medtronic appears to have no other large reduction in its share count planned.
You would see a stall next in the gross margin. Medtronic’s adjusted gross margin was 65.2% in fiscal Q1 2027, up 10 basis points from a year earlier. Management said product mix took 50 basis points off it, largely the diabetes and cardiac ablation businesses. If MiniMed stays, the diabetes part of that drag stays in Medtronic’s margin.
Predicting the exact share-price impact of a stalled exchange is difficult, though any delay risks unwinding the modest valuation premium the split-off was intended to unlock. Medtronic stock fell 21% during the 2023 bond yield shock, when the S&P 500 fell 9.5%.
What Medtronic Keeps If MiniMed Stays
The diabetes business reported 15% growth in fiscal Q1 2027, though that topline figure is flattered by an extra selling week that added an estimated 6.7 percentage points across the whole company and went unquantified for MiniMed specifically.
The swap would bring Medtronic no cash, since holders pay in shares, but the company does not appear to need any. It produced $6.1 billion of free cash flow over the past twelve months.
Management’s revenue outlook for the year has improved as well. On September 1 it raised its fiscal 2027 organic growth guide to 7.25% to 7.75%, from 7.0% before.
Management has scheduled an Investor Day for December 10 and 11. A firm closing date for the MiniMed separation at that event, still inside the fiscal year, would show the schedule management described on September 1 is holding.
How To Act On MDT?
Now you know MDT better. And that’s our purpose: to make you informed before you invest your money. However, making a bet on a single stock carries its own risks.
There is a smarter choice. Since its inception, the Trefis High Quality (HQ) Portfolio has beaten the benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking.
If you’d rather act on MDT itself:
| Play Offense | Play Defense |
|---|---|
| Learn More About MDT & Invest | Save Taxes On Capital Gain |
| Earn From MDT Cash Secured Puts | Covered Call Against MDT |